Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability

Molecular Pharmaceutics

Volumn 10, Issue 8, 2013, Pages 3112-3127

  Childs, Scott L ^a,b   Kandi, Praveen ^a   Lingireddy, Sreenivas Reddy ^a,c  

^a Renovo Research   (United States)

^b Triclinic Labs Inc   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

bioavailability; co crystal; cocrystal; danazol; dissolution; pre clinical formulation; precipitation inhibitor; solubility; spring and parachute; supersaturation; surfactant

Indexed keywords

CREMOPHOR; CREMOPHOR ELP; CRODASOL HS HP; DANAZOL; HYDROXYPROPYLCELLULOSE; KLUCEL ELF PHARM; KLUCEL LF PHARM; KOLLIDON 12 PF; KOLLIDON 90 F; KOLLIPHOR TPGS; LACTOSE; LUTROL E300; LUTROL F108NF; LUTROL F68NF; METHOCEL A15 PRM; METHOCEL E5 PRM; METHOCEL K3 PRM LV; METHYLCELLULOSE; PHARMATOSE 450M; PLASDONE K12; PLASDONE K29 32; PLASDONE S630; POLOXAMER; POLYSORBATE 80; POVIDONE; SOLUBILIZER; SOLUPLUS; SOLUTOL HS 15; TOCOFERSOLAN; UNCLASSIFIED DRUG; VANILLIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DANAZOL; MALE; POWDER DIFFRACTION; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE-ACTIVE AGENTS; X-RAY DIFFRACTION;

EID: 84881358308     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400176y     Document Type: Article

References (80)

1. Thakuria, R.; Delori, A.; Jones, W.; Lipert, M. P.; Roy, L.; Rodriguez-Hornedo, N. Pharmaceutical cocrystals and poorly soluble drugs Int. J. Pharm. 2012, 10.1016/j.ijpharm.2012.10.043
2. McNamara, D. P.; Childs, S. L.; Giordano, J.; Iarriccio, A.; Cassidy, J.; Shet, M. S.; Mannion, R.; O'Donnell, E.; Park, A. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API Pharm. Res. 2006, 23 (8) 1888-1897
3. Hickey, M. B.; Peterson, M. L.; Scoppettuolo, L. A.; Morrisette, S. L.; Vetter, A.; Guzman, H.; Remenar, J. F.; Zhang, Z.; Tawa, M. D.; Haley, S.; Zaworotko, M. J.; Almarsson, O. Performance comparison of a co-crystal of carbamazepine with marketed product Eur. J. Pharm. Biopharm. 2007, 67 (1) 112-119
4. Bak, A.; Gore, A.; Yanez, E.; Stanton, M.; Tufekcic, S.; Syed, R.; Akrami, A.; Rose, M.; Surapaneni, S.; Bostick, T.; King, A.; Neervannan, S.; Ostovic, D.; Koparkar, A. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics J. Pharm. Sci. 2008, 97 (9) 3942-3956
5. Cheney, M. L.; Shan, N.; Healey, E. R.; Hanna, M.; Wojtas, L.; Zaworotko, M. J.; Sava, V.; Song, S.; Sanchez-Ramos, J. R. Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine Cryst. Growth Des. 2010, 10 (1) 394-405
6. Jung, M.-S.; Kim, J.-S.; Kim, M.-S.; Alhalaweh, A.; Cho, W.; Hwang, S.-J.; Velaga, S. P. Bioavailability of indomethacin-saccharin cocrystals J. Pharm. Pharmacol. 2010, 62 (11) 1560-1568
7. Smith, A. J.; Kavuru, P.; Wojtas, L.; Zaworotko, M. J.; Shytle, R. D. Cocrystals of Quercetin with Improved Solubility and Oral Bioavailability Mol. Pharm. 2011, 8 (5) 1867-1876
8. Stanton, M. K.; Kelly, R. C.; Colletti, A.; Langley, M.; Munson, E. J.; Peterson, M. L.; Roberts, J.; Wells, M. Improved Pharmacokinetics of AMG 517 Through Co-crystallization Part 2: Analysis of 12 Carboxylic Acid Co-crystals J. Pharm. Sci. 2011, 100 (7) 2734-2743
9. Venczel, M.; Szvoboda, I.; Podanyi, B.; Valente, D.; Menegotto, J.; Pintye-Hodi, K.; Ujhelyi, G. Formulation Possibilities of a Weak Base with a Narrow Solubility Range Cryst. Growth Des. 2012, 12 (3) 1101-1110
10. Weyna, D. R.; Cheney, M. L.; Shan, N.; Hanna, M.; Zaworotko, M. J.; Sava, V.; Song, S.; Sanchez-Ramos, J. R. Improving Solubility and Pharmacokinetics of Meloxicam via Multiple-Component Crystal Formation Mol. Pharm. 2012, 9 (7) 2094-2102
11. Zheng, W.; Jain, A.; Papoutsakis, D.; Dannenfelser, R.-M.; Panicucci, R.; Garad, S. Selection of oral bioavailability enhancing formulations during drug discovery Drug Dev. Ind. Pharm. 2012, 38 (2) 235-247
12. Palucki, M.; Higgins, J. D.; Kwong, E.; Templeton, A. C. Strategies at the Interface of Drug Discovery and Development: Early Optimization of the Solid State Phase and Preclinical Toxicology Formulation for Potential Drug Candidates J. Med. Chem. 2010, 53 (16) 5897-5905
13. Burton, L.; Ying, W.; Gandhi, R.; West, R.; Huang, C.; Zhou, S.; Shah, K.; Chen, J.; Shen, X. Development of a precipitation-resistant solution formulation to increase in vivo exposure of a poorly water-soluble compound Int. J. Pharm. 2012, 433 (1-2) 94-101
14. Burton, L.; Ying, W.; Gandhi, R.; West, R.; Huang, C.; Zhou, S.; Shah, K.; Chen, J.; Shen, X. Development of a precipitation-resistant solution formulation to increase in vivo exposure of a poorly water-soluble compound Int. J. Pharm. 2012, 433 (1-2) 94-101
15. Brouwers, J.; Brewster, M. E.; Augustijns, P. Supersaturating Drug Delivery Systems: The Answer to Solubility-Limited Oral Bioavailability? J. Pharm. Sci. 2009, 98 (8) 2549-2572
16. Thomas, V. H.; Bhattachar, S.; Hitchingham, L.; Zocharski, P.; Naath, M.; Surendran, N.; Stoner, C. L.; El-Kattan, A. The road map to oral bioavailability: an industrial perspective Exp. Opin. Drug Metab. 2006, 2 (4) 591-608
17. Kaukonen, A. M.; Boyd, B. J.; Charman, W. N.; Porter, C. J. H. Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids Pharm. Res. 2004, 21 (2) 254-260
18. Selinger, K.; Hill, H. M.; Anslow, J. A.; Gash, D. a Liquid- Chromatographic Method for the Determination of Danazol in Human Serum J. Pharm. Biomed. Anal. 1990, 8 (1) 79-84
19. Charman, W. N.; Rogge, M. C.; Boddy, A. W.; Barr, W. H.; Berger, B. M. Absorption of danazol after administration to different sites of the gastrointestinal tract J. Clin. Pharmacol. 1993, 33 (12) 1207-1213
20. Sunesen, V. H.; Vedelsdal, R.; Kristensen, H. G.; Christrup, L.; Mullertz, A. Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug Eur. J. Pharm. Sci. 2005, 24 (4) 297-303
21. Vogt, M.; Kunath, K.; Dressman, J. B. Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients Eur. J. Pharm. Biopharm. 2008, 68 (2) 330-337
22. Vertzoni, M.; Markopoulos, C.; Symillides, M.; Goumas, C.; Imanidis, G.; Reppas, C. Luminal Lipid Phases after Administration of a Triglyceride Solution of Danazol in the Fed State and Their Contribution to the Flux of Danazol Across Caco-2 Cell Monolayers Mol. Pharmaceutics 2012, 9 (5) 1189-1198
23. Annaert, P.; Brouwers, J.; Bijnens, A.; Lammert, F.; Tack, J.; Augustijns, P. Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption Eur. J. Pharm. Sci. 2009, 39 (1-3) 15-22
24. Johnson, K. C.; Swindell, A. C. Guidance in the setting of drug particle size specifications to minimize variability in absorption Pharm. Res. 1996, 13 (12) 1795-1798
25. Takano, R.; Kataoka, M.; Yamashita, S. Integrating drug permeability with dissolution profile to develop IVIVC Biopharm. Drug Disposition 2012, 33 (7) 354-365
26. Curatolo, W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings Pharm. Sci. Technol. Today 1998, 1 (9) 387-393
27. Ozaki, S.; Minamisono, T.; Yamashita, T.; Kato, T.; Kushida, I. Supersaturation-nucleation behavior of poorly soluble drugs and its impact on the oral absorption of drugs in thermodynamically high-energy forms J. Pharm. Sci. 2012, 101 (1) 214-222
28. Bevernage, J.; Brouwers, J.; Clarysse, S.; Vertzoni, M.; Tack, J.; Annaert, P.; Augustijns, P. Drug Supersaturation in Simulated and Human Intestinal Fluids Representing Different Nutritional States J. Pharm. Sci. 2010, 99 (11) 4525-4534
29. Childs, S. L.; Hardcastle, K. I. Cocrystals of piroxicam with carboxylic acids Cryst. Growth Des. 2007, 7 (7) 1291-1304
30. Childs, S. L.; Hardcastle, K. I. Cocrystals of chlorzoxazone with carboxylic acids CrystEngComm 2007, 9 (5) 364-367
31. Childs, S. L.; Rodriguez-Hornedo, N.; Reddy, L. S.; Jayasankar, A.; Maheshwari, C.; McCausland, L.; Shipplett, R.; Stahly, B. C. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine CrystEngComm 2008, 10 (7) 856-864
32. Friscic, T.; Childs, S. L.; Rizvi, S. A. A.; Jones, W. The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome CrystEngComm 2008, 11 (3) 418-426
33. Zhang, Y.; Huo, M.; Zhou, J.; Xie, S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel Comput. Methods Programs Biomed. 2010, 99 (3) 306-314
34. Etter, M. C. Encoding and decoding hydrogen-bond patterns of organic compounds Acc. Chem. Res. 1990, 23 (4) 120-126
35. Good, D. J.; Rodriguez-Hornedo, N. Solubility Advantage of Pharmaceutical Cocrystals Cryst. Growth Des. 2009, 9 (5) 2252-2264
36. Ho, K.; Yazan, L. S.; Ismail, N.; Ismail, M. Toxicology study of vanillin on rats via oral and intra-peritoneal administration Food Chem. Toxicol. 2011, 49 (1) 25-30
37. Mancebo, A.; Trapero, Y. M.; Gonzalez, Y.; Gonzalez, B. O.; Fuentes, D.; Hernandez, O.; Hernandez, J.; Gonzalez, C.; Hernandez, Y.; Arteaga, M. E.; Subiros, N.; Bada, A. M. Repeated dose oral toxicity (13 weeks) of 4-hydroxy-3-methoxy-benzaldehyde (vanillin) to Sprague Dawley rats Toxicol. Lett. (Shannon) 2003, 144 (Suppl. 1) s57-s57
38. Vandecruys, R.; Peeters, J.; Verreck, G.; Brewster, M. E. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design Int. J. Pharm. 2007, 342 (1-2) 168-175
39. Strickley, R. G. Solubilizing excipients in oral and injectable formulations Pharm. Res. 2004, 21 (2) 201-230
40. Yamashita, T.; Kokubo, T.; Zhao, C.; Ohki, Y. Antiprecipitant Screening System for Basic Model Compounds Using Bio-Relevant Media Jala 2010, 15 (4) 306-312
41. Yamashita, T.; Ozaki, S.; Kushida, I. Solvent shift method for anti-precipitant screening of poorly soluble drugs using biorelevant medium and dimethyl sulfoxide Int. J. Pharm. 2011, 419 (1-2) 170-174
42. Dai, W.-G. In vitro methods to assess drug precipitation Int. J. Pharm. 2010, 393 (1-2) 1-16
43. Warren, D. B.; Benameur, H.; Porter, C. J. H.; Pouton, C. W. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility J. Drug Targeting 2010, 18 (10) 704-731
44. Hawley, M.; Morozowich, W. Modifying the Diffusion Layer of Soluble Salts of Poorly Soluble Basic Drugs To Improve Dissolution Performance Mol. Pharmaceutics 2010, 7 (5) 1441-1449
45. Alonzo, D. E.; Raina, S.; Zhou, D.; Gao, Y.; Zhang, G. G. Z.; Taylor, L. S. Characterizing the Impact of Hydroxypropylmethyl Cellulose on the Growth and Nucleation Kinetics of Felodipine from Supersaturated Solutions Cryst. Growth Des. 2012, 12 (3) 1538-1547
46. Alonzo, D. E.; Gao, Y.; Zhou, D.; Mo, H.; Zhang, G. G. Z.; Taylor, L. S. Dissolution and Precipitation Behavior of Amorphous Solid Dispersions J. Pharm. Sci. 2011, 100 (8) 3316-3331
47. Miller, J. M.; Beig, A.; Carr, R. A.; Spence, J. K.; Dahan, A.; Win-Win, A. Solution in Oral Delivery of Lipophilic Drugs: Supersaturation via Amorphous Solid Dispersions Increases Apparent Solubility without Sacrifice of Intestinal Membrane Permeability Mol. Pharm. 2012, 9 (7) 2009-2016
48. Van Eerdenbrugh, B.; Alonzo, D. E.; Taylor, L. S. Influence of Particle Size on the Ultraviolet Spectrum of Particulate-Containing Solutions: Implications for In-Situ Concentration Monitoring Using UV/Vis Fiber-Optic Probes Pharm. Res. 2011, 28 (7) 1643-1652
49. Greco, K.; Bogner, R. Solution-mediated phase transformation: Significance during dissolution and implications for bioavailability J. Pharm. Sci. 2012, 101 (9) 2996-3018
50. Shiraki, K.; Takata, N.; Takano, R.; Hayashi, Y.; Terada, K. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds Pharm. Res. 2008, 25 (11) 2581-2592
51. Alonzo, D. E.; Zhang, G. G. Z.; Zhou, D.; Gao, Y.; Taylor, L. S. Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution Pharm. Res. 2010, 27 (4) 608-618
52. Boni, J. E.; Brickl, R. S.; Dressman, J.; Pfefferle, M. L. Instant FaSSIF and FeSSIF-Biorelevance Meets Practicality Dissolut. Technol. 2009, 16 (3) 41-45
53. Clarysse, S.; Brouwers, J.; Tack, J.; Annaert, P.; Augustijns, P. Intestinal drug solubility estimation based on simulated intestinal fluids: Comparison with solubility in human intestinal fluids Eur. J. Pharm. Sci. 2011, 43 (4) 260-269
54. McConnell, E. L.; Basit, A. W.; Murdan, S. Measurements of rat and mouse gastrointestinal pH fluid and lymphoid tissue, and implications for in-vivo experiments J. Pharm. Pharmacol. 2008, 60 (1) 63-70
55. Liversidge, G. G.; Cundy, K. C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs Int. J. Pharm. 1995, 125 (1) 91-97
56. Takano, R.; Furumoto, K.; Shiraki, K.; Takata, N.; Hayashi, Y.; Aso, Y.; Yamashita, S. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; Prediction from a miniscale dissolution test and a physiologically-based computer simulation Pharm. Res. 2008, 25 (10) 2334-2344
57. Badawy, S. I. F.; Ghorab, M. M.; Adeyeye, C. M. Bioavailability of danazol-hydroxypropyl-beta-cylodextrin complex by different routes of administration Int. J. Pharm. 1996, 145 (1-2) 137-143
58. Badawy, S. I. F.; Ghorab, M. M.; Adeyeye, C. M. Characterization and bioavailability of danazol-hydroxypropyl beta-cyclodextrin coprecipitates Int. J. Pharm. 1996, 128 (1-2) 45-54
59. Erlich, L.; Yu, D.; Pallister, D. A.; Levinson, R. S.; Gole, D. G.; Wilkinson, P. A.; Erlich, R. E.; Reeve, L. E.; Viegas, T. X. Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules Int. J. Pharm. 1999, 179 (1) 49-53
60. Larsen, A.; Holm, R.; Pedersen, M. L.; Muellertz, A. Lipid-based Formulations for Danazol Containing a Digestible Surfactant, Labrafil M2125CS: In Vivo Bioavailability and Dynamic In Vitro Lipolysis Pharm. Res. 2008, 25 (12) 2769-2777
61. Van Speybroeck, M.; Williams, H. D.; Tri-Hung, N.; Anby, M. U.; Porter, C. J. H.; Augustijns, P. Incomplete Desorption of Liquid Excipients Reduces the in Vitro and in Vivo Performance of Self-Emulsifying Drug Delivery Systems Solidified by Adsorption onto an Inorganic Mesoporous Carrier Mol. Pharmaceutics 2012, 9 (9) 2750-2760
62. Linn, M.; Collnot, E.-M.; Djuric, D.; Hempel, K.; Fabian, E.; Kolter, K.; Lehr, C.-M. Soluplus (R) as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo Eur. J. Pharm. Sci. 2011, 45 (3) 336-343
63. Kataoka, M.; Sugano, K.; Mathews, C. d. C.; Wong, J. W.; Jones, K. L.; Masaoka, Y.; Sakuma, S.; Yamashita, S. Application of Dissolution/Permeation System for Evaluation of Formulation Effect on Oral Absorption of Poorly Water-Soluble Drugs in Drug Development Pharm. Res. 2012, 29 (6) 1485-1494
64. Anby, M. U.; Williams, H. D.; McIntosh, M.; Benameur, H.; Edwards, G. A.; Pouton, C. W.; Porter, C. J. H. Lipid Digestion as a Trigger for Supersaturation: Evaluation of the Impact of Supersaturation Stabilization on the in Vitro and in Vivo Performance of Self-Emulsifying Drug Delivery Systems Mol. Pharmaceutics 2012, 9 (7) 2063-2079
65. Babu, N. J.; Nangia, A. Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals Cryst. Growth Des. 2011, 11 (7) 2662-2679
66. Ozaki, S.; Kushida, I.; Yamashita, T.; Hasebe, T.; Shirai, O.; Kano, K. Evaluation of drug supersaturation by thermodynamic and kinetic approaches for the prediction of oral absorbability in amorphous pharmaceuticals J. Pharm. Sci. 2012, 101 (11) 4220-4230
67. Murdande, S. B.; Pikal, M. J.; Shanker, R. M.; Bogner, R. H. Solubility Advantage of Amorphous Pharmaceuticals: II. Application of Quantitative Thermodynamic Relationships for Prediction of Solubility Enhancement in Structurally Diverse Insoluble Pharmaceuticals Pharm. Res. 2010, 27 (12) 2704-2714
68. Gao, P.; Guyton, M. E.; Huang, T. H.; Bauer, J. M.; Stefanski, K. J.; Lu, Q. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations Drug Dev. Ind. Pharm. 2004, 30 (2) 221-229
69. Shanbhag, A.; Rabel, S.; Nauka, E.; Casadevall, G.; Shivanand, P.; Eichenbaum, G.; Mansky, P. Method for screening of solid dispersion formulations of low-solubility compounds-Miniaturization and automation of solvent casting and dissolution testing Int. J. Pharm. 2008, 351 (1-2) 209-218
70. Basalious, E. B.; El-Sebaie, W.; El-Gazayerly, O. Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants and Crystallization Inhibitors: Development of Controlled-Release Tablets AAPS Pharmscitech 2011, 12 (3) 799-810
71. Li, S.; Pollock-Dove, C.; Dong, L. C.; Chen, J.; Creasey, A. A.; Dai, W.-G. Enhanced Bioavailability of a Poorly Water-Soluble Weakly Basic Compound Using a Combination Approach of Solubilization Agents and Precipitation Inhibitors: A Case Study Mol. Pharmaceutics 2012, 9 (5) 1100-1108
72. Huang, N.; Rodriguez-Hornedo, N. Effect of Micelliar Solubilization on Cocrystal Solubility and Stability Cryst. Growth Des. 2010, 10 (5) 2050-2053
73. Huang, N.; Rodriguez-Hornedo, N. Engineering Cocrystal Solubility, Stability, and pH(max) by Micellar Solubilization J. Pharm. Sci. 2011, 100 (12) 5219-5234
74. Huang, N.; Rodriguez-Hornedo, N. Engineering cocrystal thermodynamic stability and eutectic points by micellar solubilization and ionization Crystengcomm 2011, 13 (17) 5409-5422
75. Dahan, A.; Miller, J. M. The Solubility-Permeability Interplay and Its Implications in Formulation Design and Development for Poorly Soluble Drugs AAPS J. 2012, 14 (2) 244-251
76. Dahan, A.; Miller, J. M.; Hoffman, A.; Amidon, G. E.; Amidon, G. L. The Solubility-Permeability Interplay in Using Cyclodextrins as Pharmaceutical Solubilizers: Mechanistic Modeling and Application to Progesterone J. Pharm. Sci. 2010, 99 (6) 2739-2749
77. Miller, J. M.; Beig, A.; Carr, R. A.; Webster, G. K.; Dahan, A. The Solubility-Permeability Interplay When Using Cosolvents for Solubilization: Revising the Way We Use Solubility-Enabling Formulations Mol. Pharmaceutics 2012, 9 (3) 581-590
78. Miller, J. M.; Beig, A.; Krieg, B. J.; Carr, R. A.; Borchardt, T. B.; Amidon, G. E.; Amidon, G. L.; Dahan, A. The Solubility-Permeability Interplay: Mechanistic Modeling and Predictive Application of the Impact of Micellar Solubilization on Intestinal Permeation Mol. Pharmaceutics 2011, 8 (5) 1848-1856
79. Ingels, F.; Beck, B.; Oth, M.; Augustijns, P. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers Int. J. Pharm. 2004, 274 (1-2) 221-232
80. Brouwers, J.; Tack, J.; Lammert, F.; Augustijns, P. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: A case study with amprenavir J. Pharm. Sci. 2006, 95 (2) 372-383